Patents Assigned to Bristol-Myers Squibb Company
-
Publication number: 20240101666Abstract: The disclosure provides a method of treating a human subject afflicted with lung cancer with a lymphocyte activation gene-3 (LAG-3) antagonist. In some aspects, the method comprises combination of the LAG-3 antagonist with an additional therapeutic agent (e.g., a programmed death-1 pathway inhibitor) and/or anti-cancer therapy (e.g., chemotherapy such as a platinum doublet chemotherapy).Type: ApplicationFiled: October 22, 2021Publication date: March 28, 2024Applicant: Bristol-Myers Squibb CompanyInventors: Laurence David TOMS, Paul Andrew BASCIANO
-
Publication number: 20240103008Abstract: The present disclosure provides matched gut and peripheral biomarkers to assess, identify and improve therapeutic measures for IBD, in particular ulcerative colitis and Crohn's disease.Type: ApplicationFiled: September 25, 2023Publication date: March 28, 2024Applicant: BRISTOL-MYERS SQUIBB COMPANYInventors: Frederic Baribaud, Aisling Hall, Jasmine Saini
-
Publication number: 20240092907Abstract: The present application relates to antibodies specifically binding to the V-domain immunoglobulin-containing suppressor of T-cell activation (VISTA) at acidic pH and their use in cancer treatment. In some embodiments, the antibodies bind specifically to human VISTA at acidic pH, but do not significantly bind to human VISTA at neutral or physiological pH.Type: ApplicationFiled: February 1, 2023Publication date: March 21, 2024Applicants: Five Prime Therapeutics, Inc., Bristol-Myers Squibb CompanyInventors: Robert J. Johnston, Arvind Rajpal, Paul O. Sheppard, Luis Borges, Andrew Rankin, Keith Sadoon Bahjat, Alan J. Korman, Andy X. Deng, Lin Hui Su, Ginger Rakestraw
-
Publication number: 20240091354Abstract: This provides pharmaceutical compositions that comprise a combination of an anti-cancer agent which is an first antibody and a second antibody. In some embodiments, the first antibody is an anti-Programmed Death-1 (PD-1) antibody. In certain embodiments, the composition is a fixed dose formulation. In certain embodiments, the composition is administered as a flat-dose. The disclosure also provides a kit for treating a subject afflicted with a disease, the kit comprising a dosage of any composition disclosed herein and instructions for using the composition in any of the disclosed methods for treating a disease.Type: ApplicationFiled: March 27, 2023Publication date: March 21, 2024Applicant: Bristol-Myers Squibb CompanyInventors: Vikram SADINENI, Yong QUAN, Wallace KASERER
-
Publication number: 20240092911Abstract: The invention provides a method of treating a tumor in a human patient comprising (i) identifying a patient as having a LAG-3 positive tumor and (ii) administering to the patient a PD-1 pathway inhibitor, a combination of a PD1 pathway inhibitor and an immune checkpoint inhibitor, a combination of a LAG-3 inhibitor and a PD-1 pathway inhibitor, or an anti-CTLA4 antibody. In some embodiments, the method further comprises identifying the patient as having a LAG-3 positive PD-L1 positive tumor. In some embodiments, the LAG-3 inhibitor is an anti-LAG-3 antibody and the PD-1 pathway inhibitor is an anti-PD-1 antibody. The methods of the invention can improve response rates to treatment with a PD-1 pathway inhibitor, a combination of a PD1 pathway inhibitor and an immune checkpoint inhibitor, or a combination of a LAG-3 inhibitor and a PD-1 pathway inhibitor.Type: ApplicationFiled: August 18, 2023Publication date: March 21, 2024Applicant: Bristol-Myers Squibb CompanyInventors: James NOVOTNY, Nils LONBERG, Cyrus HEDVAT, Raphael CLYNES, Darren LOCKE, John P. COGSWELL, Jeffrey JACKSON, Christopher HARBISON, Robin EDWARDS
-
Patent number: 11932658Abstract: Disclosed are compounds of Formula (I) to (VIII): or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or prodrug thereof, wherein R3 is a tricyclic heteroaryl group substituted with R3a and zero to 2 R3b; and Ri, R2, R3a, R3b, R4, and n are defined herein. Also disclosed are methods of using such compounds as PAR4 inhibitors, and pharmaceutical compositions comprising such compounds. These compounds are useful in inhibiting or preventing platelet aggregation, and are useful for the treatment of a thromboembolic disorder or the primary prophylaxis of a thromboembolic disorder.Type: GrantFiled: January 6, 2021Date of Patent: March 19, 2024Assignee: Bristol-Myers Squibb CompanyInventors: Xiaojun Zhang, Eldon Scott Priestley, Oz Scott Halpern, Wen Jiang, Samuel Kaye Reznik, Jeremy M. Richter
-
Patent number: 11926673Abstract: The disclosure provides for antibodies that bind CD40, including a humanized antibody. The antibodies bind CD40 and do not exhibit CD40 agonist activity. The antibodies may comprise a modified IgG1 Fc domain, and exhibit minimal activation of immature dendritic cells. Compositions comprising antibodies, methods of use for treatment of diseases involving CD40 activity, and use in the preparation of a medicament for treatment of a disease involving CD40 activity are provided.Type: GrantFiled: January 19, 2022Date of Patent: March 12, 2024Assignee: Bristol-Myers Squibb CompanyInventors: Aaron Yamniuk, Mary Struthers, Stanley R. Krystek, Jr., Akbar Nayeem, Ginger Rakestraw
-
Publication number: 20240077505Abstract: The disclosure provides a method of measuring the relative RBP-binding affinity of a liposome in a sample. In some aspects, the method comprises contacting the sample with a modified RBP associated with an immobilized surface, wherein an exterior surface of the liposome comprises a retinoid or a fat-soluble vitamin, and wherein the modified RBP binds the retinoid or the fat-soluble vitamin.Type: ApplicationFiled: December 17, 2021Publication date: March 7, 2024Applicants: Bristol-Myers Squibb Company, Meso Scale DiagnosticsInventors: Ya FU, Christopher G. LEVINS, Linda J. OBENAUER-KUTNER, Uma KAVITA, Sharadvi THATI
-
Patent number: 11919954Abstract: Provided herein are antibodies, or antigen-binding portions thereof, that specifically bind and inhibit TREM-1 signaling, wherein the antibodies do not bind to one or more Fc?Rs and do not induce the myeloid cells to produce inflammatory cytokines. Also provided are uses of such antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of autoimmune diseases.Type: GrantFiled: September 10, 2021Date of Patent: March 5, 2024Assignee: BRISTOL-MYERS SQUIBB COMPANYInventors: Achal Pashine, Michael L. Gosselin, Aaron P. Yamniuk, Derek A. Holmes, Guodong Chen, Priyanka Apurva Madia, Richard Yu-Cheng Huang, Stephen Michael Carl
-
Patent number: 11919962Abstract: Provided herein are antibodies that bind to the alpha subunit of an IL-7 receptor (IL-7R?). Also provided are uses of these antibodies in therapeutic applications, such as treatment of inflammatory diseases. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain regions of the antibodies, and vectors comprising the polynucleotides.Type: GrantFiled: April 16, 2021Date of Patent: March 5, 2024Assignee: Bristol Myers-Squibb CompanyInventors: Aaron Paul Yamniuk, Scott Ronald Brodeur, Ekaterina Deyanova, Richard Yu-Cheng Huang, Yun Wang, Alfred Robert Langish, Guodong Chen, Stephen Michael Carl, Hong Shen, Achal Mukundrao Pashine, Lin Hui Su
-
Patent number: 11919957Abstract: The disclosure provides a method for treating a subject afflicted with a tumor derived from a small cell lung cancer (SCLC) having a high tumor mutational burden (TMB) status comprising administering to the subject a monotherapy comprising an anti-PD-1 antibody or a combination therapy comprising an anti-PD-1 antibody and an anti-CTLA-4 antibody. The present disclosure also provides a method for identifying a subject suitable for treatment with an anti-PD-1 antibody or a combination therapy comprising an anti-PD-1 antibody and an anti-CTLA-4 antibody comprising measuring a TMB status of a biological sample of the subject. A high TMB status identifies the patient as suitable for treatment with an anti-PD-1 antibody or antigen-binding portion thereof. The TMB status can be determined by sequencing nucleic acids in the tumor and identifying a genomic alteration, e.g., a somatic nonsynonymous mutation, in the sequenced nucleic acids.Type: GrantFiled: October 17, 2022Date of Patent: March 5, 2024Assignee: Bristol-Myers Squibb CompanyInventors: Prabhu Seshaiyer Bhagavatheeswaran, Nicholas Allan John Botwood, Han Chang, William J. Geese, Sabine Maier, Giovanni Selvaggi, Joseph Daniel Szustakowski
-
Patent number: 11919863Abstract: The disclosure is directed to improved methods for preparing substituted quinolinylcyclohexylpropanamide compounds.Type: GrantFiled: December 16, 2021Date of Patent: March 5, 2024Assignee: Bristol-Myers Squibb CompanyInventors: Albert J. Delmonte, Benjamin M. Cohen, Kenneth Joseph Fraunhoffer, Sergei Kolotuchin, Francisco Gonzalez-Bobes, Gregory Louis Beutner, Adam Joseph Freitag, Michael Scott Bultman, Yu Fan, Prantik Maity, Ian Scott Young, Hilary Plake Beck, Maksim Osipov, Jay Patrick Powers, Maureen Kay Reilly, Hunter Paul Shunatona, James Ross Walker, Mikhail Zibinsky
-
Publication number: 20240067632Abstract: Provided herein are compounds and compositions thereof that reduce WEE1 kinase protein levels. In some embodiments, the compounds and compositions are provided for treatment WEE1 associated diseases such as cancer.Type: ApplicationFiled: June 29, 2023Publication date: February 29, 2024Applicant: Bristol-Myers Squibb CompanyInventors: John Sapienza, Jennifer R. Riggs, Jacob T. Edwards, Daniel K. Cashion, Meekyum Olivia Pierce
-
Patent number: 11912769Abstract: Methods of treating autoimmune diseases, such as systemic lupus erythematosus using domain antibodies that specifically bind human CD28 are provided. The methods may comprise at least one administration cycle comprising one dose of the domain antibody. The method reduces symptoms of systemic lupus erythematosus compared to placebo.Type: GrantFiled: January 25, 2022Date of Patent: February 27, 2024Assignee: Bristol-Myers Squibb CompanyInventors: Xavier Valencia, John P. Throup, Steven G. Nadler, Suzanne J. Suchard, Dominique Duchesne, Xiaoni Liu, Rong Shi, Diane E. Shevell, Jenny H. Xie, Marek Honczarenko
-
Patent number: 11913137Abstract: This application provides an improved screening method for the selection of target-binding proteins having desirable biophysical properties. The method combines mRNA display and yeast surface display in a way that takes advantage of the desirable attributes of both processes.Type: GrantFiled: June 8, 2021Date of Patent: February 27, 2024Assignee: Bristol-Myers Squibb CompanyInventor: Dasa Lipovsek
-
Patent number: 11912703Abstract: Disclosed are compounds of Formula (I) N-oxides, or salts thereof, wherein A, G, R1, R5, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.Type: GrantFiled: June 30, 2022Date of Patent: February 27, 2024Assignee: Bristol-Myers Squibb CompanyInventors: Alaric J. Dyckman, Dharmpal S. Dodd, Sreekantha Ratna Kumar, Durga Buchi Raju Barre, Srinivasan Kunchithapatham Duraisamy
-
Modified self-immolating moieties for use in prodrugs and conjugates and methods of using and making
Patent number: 11911483Abstract: Compounds represented by formula (I) can be used to make antibody-drug conjugates. The conjugates so made are stable in both human and mouse serum, enabling the performance of pre-clinical studies using a mouse model.Type: GrantFiled: December 18, 2020Date of Patent: February 27, 2024Assignee: Bristol-Myers Squibb CompanyInventors: Yam B. Poudel, Sanjeev Gangwar -
Publication number: 20240059799Abstract: The present invention discloses an isolated antibody that specifically binds to TL1A, comprising a heavy chain variable region (TL1A-VH) and a light chain variable region (TL1A-VL), comprising the CDR-H1, CDR-H2, and CDR-H3 sequences of a TL1A-VH sequence selected from the group consisting of SEQ ID NO: 42, SEQ ID NO: 44, SEQ ID NO: 47, SEQ ID NO: 49, SEQ ID NO: 52, SEQ ID NO: 54, SEQ ID NO: 57, SEQ ID NO: 70, SEQ ID NO: 72, SEQ ID NO: 78, SEQ ID NO: 80, SEQ ID NO: 89, SEQ ID NO: 93, SEQ ID NO: 95, SEQ ID NO: 97, SEQ ID NO: 99, SEQ ID NO: 101, SEQ ID NO: 103, SEQ ID NO: 105, SEQ ID NO: 110, SEQ ID NO: 120; and the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 18.Type: ApplicationFiled: May 9, 2023Publication date: February 22, 2024Applicants: Pfizer Inc., Bristol-Myers Squibb CompanyInventors: James Reasoner APGAR, Laird BLOOM, Fang JIN, Fridrik KARLSSON, Kimberly Ann MARQUETTE, Jessica Haewon MIN DEBARTOLO, Nicole Melissa PICHE-NICHOLAS, Lioudmila TCHISTIAKOVA
-
Publication number: 20240052035Abstract: This disclosure provides a method for treating a subject afflicted with a tumor derived from a small cell lung cancer, which method comprises administering to the subject an antibody or an antigen-binding portion thereof that specifically binds to a Programmed Death-1 (PD-1) receptor and inhibits PD-1 activity or the combination of (a) an antibody or an antigen-binding portion thereof that specifically binds to a PD-1 receptor and inhibits PD-1 activity; and (b) an antibody or an antigen-binding portion thereof that specifically binds to a Cytotoxic T-Lymphocyte Antigen-4 (CTLA-4) and inhibits CTLA-4 activity.Type: ApplicationFiled: August 15, 2023Publication date: February 15, 2024Applicant: Bristol-Myers Squibb CompanyInventor: Marina TSCHAIKA
-
Patent number: RE49880Abstract: Disclosed are compounds of Formula (I) or a salt thereof, wherein R1, R2, R3, R4, R5, m, n, and p are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.Type: GrantFiled: January 25, 2022Date of Patent: March 26, 2024Assignee: BRISTOL-MYERS SQUIBB COMPANYInventors: Alaric J. Dyckman, Dharmpal S. Dodd, John E. Macor, Christopher P. Mussari, Laxman Pasunoori, Sreekantha Ratna Kumar, Trevor C. Sherwood, Ramesh Kumar Sistla